p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy

Table 2 Multivariate analyses of ability of Shc proteins to predict failure of tamoxifen therapy

^aHR (interquartile) is the RR of relapse comparing patients in the 75th percentile of PY-Shc and 25th percentile of p66 Shc to patients in the 25th percentile of PY-Shc and 75th percentile of p66 Shc. The multivariate Cox model containing PY-Shc and p66 Shc was adjusted for nodal status, AJCC (American Joint Committee on Cancer) stage (population-based cohort), tumor stage, tumor grade, progesterone receptor status, and patient age at diagnosis. ^bSignificance using Wald statistic. CI, confidence interval; HR, hazard ratio; PY-Shc, tyrosine-phosphorylated Shc; RR, relative risk.

ISSN: 1465-542X